Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state

Manaho Komuro, Gaku Inoue, Mitsuhisa Tabata, Yoshifumi Yamada, Koichiro Atsuda, Hajime Matsubara, Junichiro Irie, Junichi Uchida, Chikako Nakajima, Hisa Izumi, Mariko Shimada, Satoru Yamada

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The study presents a comparison of the glucose-lowering effects, glycemic variability, and insulin doses during treatment with insulin degludec or insulin glargine. Methods: In this open-label, single-center, 2-way crossover study, 13 Japanese diabetic outpatients in the insulin-dependent state on basal-bolus therapy were assigned to receive either insulin glargine followed by insulin degludec, or insulin degludec followed by insulin glargine. Basal insulin doses were fixed in principle, and patients self-adjusted their bolus insulin doses. Seventy-two-hour continuous glucose monitoring was performed 2 weeks after switching the basal insulin. Results: Mean blood glucose (mg/dL) was not significantly different between insulin degludec and insulin glargine over 48 hours (141.8 ± 35.2 vs 151.8 ± 43.3), at nighttime (125.6 ± 40.0 vs 124.7 ± 50.4), or at daytime (149.3 ± 37.1 vs 163.3 ± 44.5). The standard deviation (mg/dL) was also similar (for 48 hours: 48.9 ± 19.4 vs 50.3 ± 17.3; nighttime: 18.7 ± 14.3 vs 13.7 ± 6.7; daytime: 49.3 ± 20.0 vs 44.3 ± 17.7). Other indices of glycemic control, glycemic variability, and hypoglycemia were similar for both insulin analogs. Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 ± 0.20 vs 0.46 ± 0.22 U/kg/day, P =.028; TDBD: 0.27 ± 0.13 vs 0.30 ± 0.14 U/kg/day, P =.036). Conclusions: Insulin degludec and insulin glargine provided effective and stable glycemic control. Insulin degludec required lower TDD and TDBD in this population of patients.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalJournal of diabetes science and technology
Volume9
Issue number3
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Insulin
insulin degludec
Insulin Glargine
Glycemic Index
Glucose
Hypoglycemia
Cross-Over Studies
Blood Glucose
Labels
Outpatients

Keywords

  • Clinical trial
  • Continuous glucose monitoring
  • Insulin degludec
  • Insulin glargine
  • Insulin therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. / Komuro, Manaho; Inoue, Gaku; Tabata, Mitsuhisa; Yamada, Yoshifumi; Atsuda, Koichiro; Matsubara, Hajime; Irie, Junichiro; Uchida, Junichi; Nakajima, Chikako; Izumi, Hisa; Shimada, Mariko; Yamada, Satoru.

In: Journal of diabetes science and technology, Vol. 9, No. 3, 01.05.2015, p. 632-638.

Research output: Contribution to journalArticle

Komuro, M, Inoue, G, Tabata, M, Yamada, Y, Atsuda, K, Matsubara, H, Irie, J, Uchida, J, Nakajima, C, Izumi, H, Shimada, M & Yamada, S 2015, 'Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state', Journal of diabetes science and technology, vol. 9, no. 3, pp. 632-638. https://doi.org/10.1177/1932296814564396
Komuro, Manaho ; Inoue, Gaku ; Tabata, Mitsuhisa ; Yamada, Yoshifumi ; Atsuda, Koichiro ; Matsubara, Hajime ; Irie, Junichiro ; Uchida, Junichi ; Nakajima, Chikako ; Izumi, Hisa ; Shimada, Mariko ; Yamada, Satoru. / Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. In: Journal of diabetes science and technology. 2015 ; Vol. 9, No. 3. pp. 632-638.
@article{b45a538776e348b6a74a2223de5f5f0e,
title = "Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state",
abstract = "Background: The study presents a comparison of the glucose-lowering effects, glycemic variability, and insulin doses during treatment with insulin degludec or insulin glargine. Methods: In this open-label, single-center, 2-way crossover study, 13 Japanese diabetic outpatients in the insulin-dependent state on basal-bolus therapy were assigned to receive either insulin glargine followed by insulin degludec, or insulin degludec followed by insulin glargine. Basal insulin doses were fixed in principle, and patients self-adjusted their bolus insulin doses. Seventy-two-hour continuous glucose monitoring was performed 2 weeks after switching the basal insulin. Results: Mean blood glucose (mg/dL) was not significantly different between insulin degludec and insulin glargine over 48 hours (141.8 ± 35.2 vs 151.8 ± 43.3), at nighttime (125.6 ± 40.0 vs 124.7 ± 50.4), or at daytime (149.3 ± 37.1 vs 163.3 ± 44.5). The standard deviation (mg/dL) was also similar (for 48 hours: 48.9 ± 19.4 vs 50.3 ± 17.3; nighttime: 18.7 ± 14.3 vs 13.7 ± 6.7; daytime: 49.3 ± 20.0 vs 44.3 ± 17.7). Other indices of glycemic control, glycemic variability, and hypoglycemia were similar for both insulin analogs. Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 ± 0.20 vs 0.46 ± 0.22 U/kg/day, P =.028; TDBD: 0.27 ± 0.13 vs 0.30 ± 0.14 U/kg/day, P =.036). Conclusions: Insulin degludec and insulin glargine provided effective and stable glycemic control. Insulin degludec required lower TDD and TDBD in this population of patients.",
keywords = "Clinical trial, Continuous glucose monitoring, Insulin degludec, Insulin glargine, Insulin therapy",
author = "Manaho Komuro and Gaku Inoue and Mitsuhisa Tabata and Yoshifumi Yamada and Koichiro Atsuda and Hajime Matsubara and Junichiro Irie and Junichi Uchida and Chikako Nakajima and Hisa Izumi and Mariko Shimada and Satoru Yamada",
year = "2015",
month = "5",
day = "1",
doi = "10.1177/1932296814564396",
language = "English",
volume = "9",
pages = "632--638",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state

AU - Komuro, Manaho

AU - Inoue, Gaku

AU - Tabata, Mitsuhisa

AU - Yamada, Yoshifumi

AU - Atsuda, Koichiro

AU - Matsubara, Hajime

AU - Irie, Junichiro

AU - Uchida, Junichi

AU - Nakajima, Chikako

AU - Izumi, Hisa

AU - Shimada, Mariko

AU - Yamada, Satoru

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: The study presents a comparison of the glucose-lowering effects, glycemic variability, and insulin doses during treatment with insulin degludec or insulin glargine. Methods: In this open-label, single-center, 2-way crossover study, 13 Japanese diabetic outpatients in the insulin-dependent state on basal-bolus therapy were assigned to receive either insulin glargine followed by insulin degludec, or insulin degludec followed by insulin glargine. Basal insulin doses were fixed in principle, and patients self-adjusted their bolus insulin doses. Seventy-two-hour continuous glucose monitoring was performed 2 weeks after switching the basal insulin. Results: Mean blood glucose (mg/dL) was not significantly different between insulin degludec and insulin glargine over 48 hours (141.8 ± 35.2 vs 151.8 ± 43.3), at nighttime (125.6 ± 40.0 vs 124.7 ± 50.4), or at daytime (149.3 ± 37.1 vs 163.3 ± 44.5). The standard deviation (mg/dL) was also similar (for 48 hours: 48.9 ± 19.4 vs 50.3 ± 17.3; nighttime: 18.7 ± 14.3 vs 13.7 ± 6.7; daytime: 49.3 ± 20.0 vs 44.3 ± 17.7). Other indices of glycemic control, glycemic variability, and hypoglycemia were similar for both insulin analogs. Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 ± 0.20 vs 0.46 ± 0.22 U/kg/day, P =.028; TDBD: 0.27 ± 0.13 vs 0.30 ± 0.14 U/kg/day, P =.036). Conclusions: Insulin degludec and insulin glargine provided effective and stable glycemic control. Insulin degludec required lower TDD and TDBD in this population of patients.

AB - Background: The study presents a comparison of the glucose-lowering effects, glycemic variability, and insulin doses during treatment with insulin degludec or insulin glargine. Methods: In this open-label, single-center, 2-way crossover study, 13 Japanese diabetic outpatients in the insulin-dependent state on basal-bolus therapy were assigned to receive either insulin glargine followed by insulin degludec, or insulin degludec followed by insulin glargine. Basal insulin doses were fixed in principle, and patients self-adjusted their bolus insulin doses. Seventy-two-hour continuous glucose monitoring was performed 2 weeks after switching the basal insulin. Results: Mean blood glucose (mg/dL) was not significantly different between insulin degludec and insulin glargine over 48 hours (141.8 ± 35.2 vs 151.8 ± 43.3), at nighttime (125.6 ± 40.0 vs 124.7 ± 50.4), or at daytime (149.3 ± 37.1 vs 163.3 ± 44.5). The standard deviation (mg/dL) was also similar (for 48 hours: 48.9 ± 19.4 vs 50.3 ± 17.3; nighttime: 18.7 ± 14.3 vs 13.7 ± 6.7; daytime: 49.3 ± 20.0 vs 44.3 ± 17.7). Other indices of glycemic control, glycemic variability, and hypoglycemia were similar for both insulin analogs. Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 ± 0.20 vs 0.46 ± 0.22 U/kg/day, P =.028; TDBD: 0.27 ± 0.13 vs 0.30 ± 0.14 U/kg/day, P =.036). Conclusions: Insulin degludec and insulin glargine provided effective and stable glycemic control. Insulin degludec required lower TDD and TDBD in this population of patients.

KW - Clinical trial

KW - Continuous glucose monitoring

KW - Insulin degludec

KW - Insulin glargine

KW - Insulin therapy

UR - http://www.scopus.com/inward/record.url?scp=84942318039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942318039&partnerID=8YFLogxK

U2 - 10.1177/1932296814564396

DO - 10.1177/1932296814564396

M3 - Article

C2 - 25526758

AN - SCOPUS:84942318039

VL - 9

SP - 632

EP - 638

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -